Skip to main content
. 2023 May 31;6(5):e2315315. doi: 10.1001/jamanetworkopen.2023.15315

Figure 2. Safety Outcome.

Figure 2.

The observed frequency (A), relative risk (B), and risk reduction (C) of moderate or severe neurodevelopmental impairment (NDI) or death in the hydrocortisone vs placebo treatment groups by quartile (Q) of baseline estimated risk of grades 2 to 3 bronchopulmonary dysplasia (BPD) or death. Symbols (circles, squares, and triangles) represent estimated values by quartile of baseline risk; error bars indicate 95% CIs. The horizontal orange lines indicate the model estimated results; the horizontal blue lines and dashed lines indicate the overall trial result and 95% CIs, respectively. Moderate or severe NDI or death did not differ by interaction between treatment group and baseline risk for grades 2 to 3 BPD or death.